TG Therapeutics Inc (STU:NKB2)
€ 15.344 -0.116 (-0.75%) Market Cap: 2.33 Bil Enterprise Value: 2.24 Bil PE Ratio: 74.14 PB Ratio: 15.74 GF Score: 73/100

TG Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 05:45PM GMT
Release Date Price: €10.06 (+1.29%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. So we can get started. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is TG Therapeutics. Presenting on behalf of the company is CEO Mike Weiss. The Q&A session we're doing in the room, there'll be mics circulating around for those who want to ask a question, and you can also submit them in the digital conference book, and I can work them in.

So with that, Mike. Thanks.

Michael S. Weiss
TG Therapeutics, Inc. - Chairman, CEO & President

Thanks, Eric, and thanks, everyone, for joining us this morning. Before I get started, I just mentioned that I probably will be making some forward-looking statements. So I do encourage folks who are interested to review our public disclosure documents available on the Internet and the risk factors that go with those.

All right. So let's get started here. We've got exciting news that we announced about 1.5 weeks ago. Ublituximab, is our lead development product

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot